Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Weill Medical College of Cornell University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00538668
First received: October 2, 2007
Last updated: November 4, 2010
Last verified: November 2010

October 2, 2007
November 4, 2010
August 2007
January 2011   (final data collection date for primary outcome measure)
  • Define the PK and dosimetry of 177Lu-J591 [ Time Frame: Perform imaging and pharmacokinetic (PK) sampling during the first two weeks of treatment. ] [ Designated as safety issue: No ]
  • Determine the cumulative maximum tolerated dose of 177Lu-J591 in a 2 week dose-fractionation regimen. [ Time Frame: Will be determined baesd on toxicity experienced by patients at each dose level. ] [ Designated as safety issue: Yes ]
  • Determine the myelotoxicity of fractionated dose of 177Lu-J591 [ Time Frame: Lab tests will be performed weekly. ] [ Designated as safety issue: Yes ]
  • Define the preliminary efficacy (response rate) of 177Lu-J591 [ Time Frame: PSA will be evaluated at baseline and weeks 6, 10 and 14. Scan will be perfoemed at baseline and week 14. ] [ Designated as safety issue: No ]
  • Define the PK and dosimetry of 177Lu-J591 [ Time Frame: Perform imaging and pharmacokinetic (PK) sampling during the first two weeks of treatment. ]
  • Determine the cumulative maximum tolerated dose of 177Lu-J591 in a 2 week dose-fractionation regimen.
  • Determine the myelotoxicity of fractionated dose of 177Lu-J591
  • Define the preliminary efficacy (response rate) of 177Lu-J591
Complete list of historical versions of study NCT00538668 on ClinicalTrials.gov Archive Site
  • Monitor biochemical (PSA) and/or measurable disease response and duration. [ Time Frame: PSA will be evaluated at baseline and weeks 6, 10 and 14. Scan will be perfoemed at baseline and week 14. ] [ Designated as safety issue: No ]
  • Estimate radiation dosimetry of 177Lu-J591 and correlate toxicity with radiation dosimetry. [ Time Frame: Total body images will be obtained on day 0 at 1-4 hours after treatment, day 1, once during days 3-6, days 7 and 14 ] [ Designated as safety issue: No ]
  • Monitor biochemical (PSA) and/or measurable disease response and duration.
  • Estimate radiation dosimetry of 177Lu-J591 and correlate toxicity with radiation dosimetry.
Not Provided
Not Provided
 
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer Using 177Lu-J591 Antibody: Dose Fractionation Regimen

The purpose of this study is to test the safety of the experimental drug, 177Lu-J591 and see what effects (good and bad) it has on your prostate cancer. Another purpose is to find the highest dose of the drug that can be given without causing severe side effects.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Drug: 117Lu-J591
There will be 8 groups of patients. The first group will receive 20 units of test drug and the 8th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
  • Experimental: 1
    20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 2
    25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 3
    30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 4
    35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 5
    40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 6
    45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 7
    50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
  • Experimental: 8
    55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
    Intervention: Drug: 117Lu-J591
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
July 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologic diagnosis (recent or remote) of prostate adenocarcinoma.
  2. Progressive, castrate metastatic carcinoma of the prostate defined by presence of metastatic disease on imaging and:

    • progressive tumor lesions on CT or MRI and/or
    • new osseous lesions on bone scan and/or
    • rising PSA
  3. Rising PSA on 3 serial determinations over a period of ≥ 2 weeks.
  4. If patient is being treated with an LHRH analog, the drug:

    • must be maintained for the duration of this study or
    • must be terminated ≥ 10 weeks prior to entry (for 28 day depot preparations) or 24 weeks (for 3 month depot preparations) or 32 weeks (for 4 month depot preparation).
  5. Platelet count > 150,000/mm3.
  6. Absolute neutrophil count (ANC) ≥ 2,000/mm3
  7. Normal coagulation profile (PT, PTT), unless on a stable anticoagulation regimen
  8. Hematocrit > 30% or Hemoglobin > 10g/dL without blood transfusion dependency
  9. Patients of child bearing potential must agree to use an effective method of contraception.
  10. Patient must have progressed following discontinuation of anti-androgen therapy, if received.
  11. Serum testosterone < 50 ng/ml.

Exclusion Criteria:

  1. Prior aspirin and/or non-steroidal anti-inflammatory agents within 1 week of study treatment.
  2. Prior corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment, except for low dose maintenance prednisone or hydrocortisone (i.e. for adrenal insufficiency) on a stable dose at the investigator's discretion.
  3. Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
  4. Prior radiation therapy encompassing >25% of expected red marrow distribution.
  5. Prior treatment with 89Strontium (Metastron®) or 153Samarium (Quadramet®). CNS metastasis.
  6. History of seizure and/or stroke within past 2 years
  7. History of HIV
  8. Serum creatinine > 2.0
  9. SGOT > 2x ULN
  10. Bilirubin (total) >1.5x ULN
  11. Serum calcium > 12.5
  12. Active infection
  13. Active angina pectoris or NY Heart Association Class III-IV.
  14. Karnofsky Performance Status < 60; ECOG Performance Status > 2.
  15. Life expectancy < 6 months
  16. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
  17. Prior treatment with monoclonal Ab J591 labeled with therapeutic doses of 177Lu or 90Y
  18. Other investigational therapy within 4 weeks of treatment
Male
21 Years to 85 Years
No
Not Provided
United States
 
NCT00538668
0602008378, Repetitive dosing 177Lu-J591
Yes
Scott Tagawa, M.D. / Principal Investigator, Weill Medical College of Cornell University
Weill Medical College of Cornell University
Not Provided
Principal Investigator: Scott Tagawa, M.D. Weill Medical College of Cornell University
Weill Medical College of Cornell University
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP